Revenue and Profitability - Revenue for Q3 2025 reached ¥164,399,742.15, an increase of 59.45% year-over-year[5] - Net profit attributable to shareholders decreased by 23.50% to ¥23,353,545.93 in Q3 2025[5] - Net profit excluding non-recurring items was ¥19,271,570.19, down 20.76% compared to the same period last year[5] - The company's operating revenue for the first three quarters of 2025 reached ¥434.70 million, a 32.47% increase compared to ¥328.16 million in the same period of 2024[10] - The net profit for the reporting period, excluding the impact of the newly acquired Foster Pharmaceuticals, was ¥36.76 million, reflecting a 20.43% year-on-year growth[10] - Net profit for the current period was ¥99,238,347.92, representing a 3.0% increase compared to ¥96,335,195.65 in the previous period[29] Assets and Liabilities - Total assets increased by 8.52% to ¥2,549,790,054.85 as of September 30, 2025[5] - The total liabilities increased to CNY 181,886,840.09 from CNY 71,162,838.83, indicating a significant rise of approximately 156.5%[24] - The company reported a total current assets of CNY 1,835,895,685.80 as of September 30, 2025, down from CNY 1,944,260,056.93 at the beginning of the period, representing a decrease of approximately 5.57%[22] - The total non-current assets increased to CNY 713,894,369.05 from CNY 405,359,118.69, showing an increase of approximately 76%[23] Cash Flow - Cash flow from operating activities showed a significant decline of 55.23%, totaling ¥47,723,128.59 year-to-date[5] - Cash inflow from operating activities totaled ¥393,575,655.90, compared to ¥368,404,311.40 in the previous period, reflecting a growth of 6.9%[31] - The net cash flow from operating activities was $47,723,128.59, a decrease of 55.3% compared to $106,599,489.96 in the previous period[32] - The total cash inflow from investment activities was $4,031,521,486.09, significantly up from $739,050,803.89, marking an increase of 445.5%[32] - The net cash flow from investment activities was $354,383,240.84, recovering from a negative cash flow of -$950,298,018.67 in the previous period[32] - The total cash inflow from financing activities was $79,601,100.00, compared to $11,500,000.00 in the previous period, representing an increase of 592.3%[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,024, with the largest shareholder holding 47.40% of the shares[13] - The company adjusted the grant price for the 2024 restricted stock incentive plan from CNY 22.30 per share to CNY 21.91 per share due to mid-year equity distribution[17] - The company plans to grant 179,000 shares of the second category of restricted stock to 13 eligible participants at the adjusted price of CNY 21.91 per share on July 2, 2025[17] Acquisitions and Goodwill - The company acquired a subsidiary, resulting in goodwill of ¥71,721,165.16[9] - The company completed the acquisition of 100% equity in Hangzhou Foster Pharmaceutical Co., Ltd., with the first phase of the equity transfer completed on July 9, 2025, resulting in the company holding 85% of the shares[19] - The company acquired Hangzhou Foster Pharmaceuticals in July 2025, which reported an operating revenue of ¥20.93 million and a net loss of ¥13.41 million during the reporting period[10] - The company's goodwill increased to CNY 71,721,165.16, reflecting the impact of recent acquisitions[23] Financial Performance Metrics - The weighted average return on equity decreased to 1.01%, down 0.36 percentage points from the previous year[5] - Basic earnings per share increased to ¥0.93 from ¥0.90, while diluted earnings per share rose to ¥0.92 from ¥0.89[30] - Total operating costs amounted to ¥336,820,135.14, up 47.4% from ¥228,599,500.59 year-over-year[28] - Research and development expenses were ¥30,612,903.47, up from ¥26,225,248.09, indicating a focus on innovation[28] Tax and Financial Charges - The company reported a significant increase in tax and additional charges by 82.77% to ¥4.67 million, primarily due to increased additional taxes[10] - The deferred income tax liabilities increased by 768.82% to ¥8.15 million, mainly due to the recognition of deferred taxes from the newly acquired assets of Foster Pharmaceuticals[10] Financial Adjustments - The financial expenses decreased by 67.06% to -¥8.20 million, attributed to adjustments in cash management product types[10] - The investment income surged by 975.39% to ¥12.61 million, due to changes in cash management product types[10] - The company reported a financial income of ¥12,832,185.57, down from ¥28,050,784.16, suggesting a decrease in interest income[28] Audit Information - The company did not undergo an audit for the third quarter financial report[34]
昊帆生物(301393) - 2025 Q3 - 季度财报